Organoids are tiny, self-organized, three-dimensional tissue cultures that are derived from stem cells. Such cultures can be crafted to replicate much of the complexity of an organ or to express selected aspects of it, like producing only certain types of cells. Organoids grow from stem cells—cells that can divide indefinitely and produce different types of cells as part of their progeny. Organoids can range in size from less than the width of a hair to five millimeters.
Thermo Fisher Scientific Inc and Merck KGaA – Notable Market Players in Organoids Market
Key driving factors include the factors driving organoids market growth are the growing adoption of personalized drugs. Increasing demand for tumor modeling and biobanking. However, issues related to the incorporation of organoids into existing workflows and the dearth of skilled professionals hinder organoids market growth.
The organoids market is majorly comprised of top players involving STEMCELL Technologies Inc; Cellesce Ltd; Hubrecht Organoid Technology; Definigen; Organoid Therapeutics; PeproTech, Inc; Thermo Fisher Scientific Inc; Corning Inc; Merck KGaA, and InSphero. among others.
The companies listed above are implementing various strategies such as product launches, acquisitions, mergers, and partnerships, which have resulted in the company’s growth and, in turn, have brought about various changes in the worldwide market. Additionally, the companies have adopted several inorganic and organic strategies for accelerating their growth and improving their market position.
Below is the list of the growth strategies done by the players operating in the organoids market:
|
Year |
News |
| May -2020 | UK-headquartered iPSC disease modeling company DefiniGEN has identified iPSC-derived intestinal organoids that could be used to help structure in vitro studies of the biology of SARS-CoV2 infection across cohorts of multiple patients. |
| Aug-2021 | InSphero AG announced that it is making its proprietary, patented 96- and 384-microwell plates available to researchers, enabling them to access the same plate technology used in the company’s flagship, assay-ready 3D InSight Human Liver Microtissues. The plates, engineered specifically for 3D cultures of spheroids and organoids, are available via InSphero’s online R&D Solutions Store. |
| Aug-2021 | STEMCELL Technologies and Hubrecht Organoid Technology (HUB) have signed an agreement to use tissue-derived organoids—including lung, intestinal, and liver organoids—in preclinical toxicology screening and non-cancer drug development services to be offered by the Contract Assay Services division of STEMCELL. |
| Feb-2023 | Thermo Fisher Scientific and Celltrio collaborated to bring a fully automated cell culture system to biotherapeutics customers. The collaboration will integrate the Thermo Scientific Momentum workflow scheduling software with the Celltrio RoboCell cell line automation platform to address the unmet market need for high-throughput automated cell line culturing and maintenance. |
| Apr-2023 | InSphero AG announced that the company is making their patented Akura 96 and 384 Spheroid Microplates available to researchers in the Indian market by signing a distribution agreement with Bionova Supplies in the Biotechnology and Scientific Instruments field in India. |
